267 related articles for article (PubMed ID: 31009835)
21. A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.
Kirschbaum M; Gojo I; Goldberg SL; Bredeson C; Kujawski LA; Yang A; Marks P; Frankel P; Sun X; Tosolini A; Eid JE; Lubiniecki GM; Issa JP
Br J Haematol; 2014 Oct; 167(2):185-93. PubMed ID: 25040094
[TBL] [Abstract][Full Text] [Related]
22. [Short-term efficacy of venetoclax combined with azacitidine in acute myeloid leukemia: a single-institution experience].
Yu WJ; Jia JS; Wang J; Tang FF; Gong LZ; Liu XH; Zhu XL; Zhao XS; Huang XJ; Jiang H
Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):134-140. PubMed ID: 35381674
[No Abstract] [Full Text] [Related]
23. Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
Assi R; Kantarjian HM; Kadia TM; Pemmaraju N; Jabbour E; Jain N; Daver N; Estrov Z; Uehara T; Owa T; Cortes JE; Borthakur G
Cancer; 2018 Jul; 124(13):2758-2765. PubMed ID: 29660836
[TBL] [Abstract][Full Text] [Related]
24. Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes.
Borthakur G; Huang X; Kantarjian H; Faderl S; Ravandi F; Ferrajoli A; Torma R; Morris G; Berry D; Issa JP
Leuk Lymphoma; 2010 Jan; 51(1):73-8. PubMed ID: 20017599
[TBL] [Abstract][Full Text] [Related]
25. [A clinical trial for homoharringtonine and low-dose cytosine arabinoside combined with G-CSF or GM-CSF to treat the relapsed or refractory acute myeloid leukemia (AML), geriatric AML and advanced myelodysplastic syndromes].
Xu J; Xu CG; Liu T; Xiang B; Chang H; He C
Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Jan; 40(1):129-32. PubMed ID: 19292062
[TBL] [Abstract][Full Text] [Related]
26. Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial.
Taylor J; Mi X; Penson AV; Paffenholz SV; Alvarez K; Sigler A; Chung SS; Rampal RK; Park JH; Stein EM; Tallman MS; Sen F; Gönen M; Abdel-Wahab O; Klimek VM
Lancet Haematol; 2020 Aug; 7(8):e566-e574. PubMed ID: 32735836
[TBL] [Abstract][Full Text] [Related]
27. Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome.
Lee ST; Jang JH; Suh HC; Hahn JS; Ko YW; Min YH
Am J Hematol; 2001 Dec; 68(4):237-45. PubMed ID: 11754412
[TBL] [Abstract][Full Text] [Related]
28. Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000.
Kantarjian HM; DiNardo CD; Nogueras-Gonzalez GM; Kadia TM; Jabbour E; Bueso-Ramos CE; O'Brien SM; Konopleva M; Jain NB; Daver NG; Shpall EJ; Champlin RE; Simkins A; Garcia-Manero G; Keating MJ; Huang X; Cortes JE; Pierce SA; Ravandi F; Freireich EJ
Cancer; 2018 Jun; 124(12):2534-2540. PubMed ID: 29645075
[TBL] [Abstract][Full Text] [Related]
29. Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia.
Wei A; Tan P; Perruzza S; Govindaraj C; Fleming S; McManus J; Avery S; Patil S; Stevenson W; Plebanski M; Spencer A
Br J Haematol; 2015 Apr; 169(2):199-210. PubMed ID: 25643589
[TBL] [Abstract][Full Text] [Related]
30. Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison?
Platzbecker U; Germing U
Leukemia; 2013 Sep; 27(9):1813-9. PubMed ID: 23644421
[TBL] [Abstract][Full Text] [Related]
31. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome.
Daver N; Kantarjian H; Ravandi F; Estey E; Wang X; Garcia-Manero G; Jabbour E; Konopleva M; O'Brien S; Verstovsek S; Kadia T; Dinardo C; Pierce S; Huang X; Pemmaraju N; Diaz-Pines-Mateo M; Cortes J; Borthakur G
Leukemia; 2016 Feb; 30(2):268-73. PubMed ID: 26365212
[TBL] [Abstract][Full Text] [Related]
32. Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies.
Senapati J; Fiskus WC; Daver N; Wilson NR; Ravandi F; Garcia-Manero G; Kadia T; DiNardo CD; Jabbour E; Burger J; Short NJ; Alvarado Y; Jain N; Masarova L; Issa GC; Qiao W; Khoury JD; Pierce S; Miller D; Sasaki K; Konopleva M; Bhalla KN; Borthakur G; Pemmaraju N
Clin Cancer Res; 2023 Nov; 29(21):4352-4360. PubMed ID: 37585491
[TBL] [Abstract][Full Text] [Related]
33. Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
Gao S; Li Z; Fu JH; Hu XH; Xu Y; Jin ZM; Tang XW; Han Y; Chen SN; Sun AN; Wu DP; Qiu HY
Asian Pac J Cancer Prev; 2015; 16(15):6627-32. PubMed ID: 26434886
[TBL] [Abstract][Full Text] [Related]
34. A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML.
Ramsingh G; Westervelt P; Cashen AF; Uy GL; Stockerl-Goldstein K; Abboud CN; Bernabe N; Monahan R; DiPersio JF; Vij R
Leukemia; 2013 Mar; 27(3):725-8. PubMed ID: 22828444
[No Abstract] [Full Text] [Related]
35. Azacitidine and lenalidomide as an alternative treatment for refractory acute myeloid leukemia: a case report.
Todaro J; Bollmann PW; Rother ET; del Giglio A
Sao Paulo Med J; 2015; 133(3):271-4. PubMed ID: 25250799
[TBL] [Abstract][Full Text] [Related]
36. Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.
Pollyea DA; Zehnder J; Coutre S; Gotlib JR; Gallegos L; Abdel-Wahab O; Greenberg P; Zhang B; Liedtke M; Berube C; Levine R; Mitchell BS; Medeiros BC
Haematologica; 2013 Apr; 98(4):591-6. PubMed ID: 23242596
[TBL] [Abstract][Full Text] [Related]
37. Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome.
Raffoux E; Cras A; Recher C; Boëlle PY; de Labarthe A; Turlure P; Marolleau JP; Reman O; Gardin C; Victor M; Maury S; Rousselot P; Malfuson JV; Maarek O; Daniel MT; Fenaux P; Degos L; Chomienne C; Chevret S; Dombret H
Oncotarget; 2010 May; 1(1):34-42. PubMed ID: 21293051
[TBL] [Abstract][Full Text] [Related]
38. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.
Cashen AF; Schiller GJ; O'Donnell MR; DiPersio JF
J Clin Oncol; 2010 Feb; 28(4):556-61. PubMed ID: 20026803
[TBL] [Abstract][Full Text] [Related]
39. A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia.
Zeidan AM; Smith BD; Carraway HE; Gojo I; DeZern A; Gore SD
Br J Haematol; 2017 Jan; 176(2):241-247. PubMed ID: 27790720
[TBL] [Abstract][Full Text] [Related]
40. Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS.
Ossenkoppele GJ; Breems DA; Stuessi G; van Norden Y; Bargetzi M; Biemond BJ; A von dem Borne P; Chalandon Y; Cloos J; Deeren D; Fehr M; Gjertsen B; Graux C; Huls G; Janssen JJJW; Jaspers A; Jongen-Lavrencic M; de Jongh E; Klein SK; van der Klift M; van Marwijk Kooy M; Maertens J; Michaux L; van der Poel MWM; van Rhenen A; Tick L; Valk P; Vekemans MC; van der Velden WJFM; de Weerdt O; Pabst T; Manz M; Löwenberg B;
Leukemia; 2020 Jul; 34(7):1751-1759. PubMed ID: 32020044
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
